| |
| |
|
Additional information for proper use:
Treatment duration
Your doctor may instruct you to use Enstilar twice a week once your psoriasis has healed or is almost healed. Enstilar should be applied twice a week for two non-consecutive days (e.g., Wednesday and Saturday) on all previously affected areas by psoriasis. Between applications, there should be 2-3 days without Enstilar treatment.
If symptoms reappear, you should use Enstilar once a day as indicated above and contact your doctor to review your treatment.
Using more Enstilar than you should
Important:A 60 g Enstilar container should last at least 4 days (see section 2 "Special precautions").If you use other medications containing calcipotriol, the total amount of calcipotriol-containing medications, including Enstilar, should not exceed 15 grams per day.Consult your doctor if you have used a dose higher than recommended.
Excessive use of this medicationmay cause a problem with your blood calcium levels, which usually normalize when the treatment is stopped.
Long-term and excessive use may also cause your adrenal glands to malfunction (adrenal glands are located near the kidneys and produce hormones).
See section 4 for additional information.
In case of overdose or accidental ingestion, go immediately to a medical center or callthe Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount used.
If you forget to use Enstilar
Do not apply a double dose to compensate for the missed doses.
If you interrupt Enstilar treatment
Enstilar treatment should be completed as indicated by your doctor. You may need to stop using this medication gradually, especially if you have been using it for a long time.
If you have any other questions about using this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Side effects observed with Enstilar:
Rare side effects (may affect up to 1 in 100 people):
Unknown frequency (frequency that cannot be estimated from available data)
This medicine contains betamethasone (a potent steroid) and calcipotriol. You may therefore experience the following side effects. These side effects are more likely to occur if Enstilar is used for a prolonged period, when the area is covered, when used in skin folds (e.g. elbows, axillae, or under the breasts), or when used on large areas of skin:
If you experience any of the side effects mentioned, inform your doctor immediately.
Less severe side effects caused by calcipotriol or betamethasone include::
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through theSistema Español de Farmacovigilancia de Medicamentos de Uso Humano: www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Warning:Extremely flammable aerosol. Pressurized container: May explode if heated. Protect from sunlight. Do not expose to temperatures above 122°F. Do not pierce or burn, even if empty. Do not spray onto an open flame or other ignition source. Keep away from sparks, open flames, and other ignition sources. Do not smoke near the container. |
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the container after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 86°F.
The container must be disposed of after 6months of the first opening.
Medicines should not be disposed of through the drains or in the trash. Deposit the containers and medicines that you no longer need at the SIGRE point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines that you no longer need. In this way, you will help protect the environment.
Composition of Enstilar
The active principles are:
Calcipotriol and betamethasone.
One gram of cutaneous foam contains 50micrograms of calcipotriol (as monohydrate) and 0.5mg of betamethasone (as dipropionate).
Theother components are:
Liquid paraffin
Polyoxypropylene stearyl ether
All-rac-α-tocopherol
White vaseline
Butilhydroxytoluene (E321)
Butane
Dimethyl ether
Appearance of Enstilar and contents of the container
Enstilar is a cutaneous foam.
After spraying, a white or off-white, non-expansive foam is formed that collapsesgradually after spraying.
Aluminum container with an internal coating of polyamide-imide, provided with a pump and continuous valve.
The container contains 60g of foam, excluding the amount corresponding to the propellants.
Container sizes: 60g, 2 containers of 60g.
Only some container sizes may be commercially available.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
LEO Pharma A/S
Industriparken 55
DK-2750 Ballerup
Denmark
Responsible for manufacturing
LEO Laboratories Ltd.
285 Cashel Road, Crumlin
Dublin 12
Ireland
LEO Pharma A/S
Industriparken 55
DK-2750 Ballerup
Denmark
This medicinal product is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
Enstilar:Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, United Kingdom (Northern Ireland)
Enstilum:Belgium, Luxembourg, Romania, Slovenia
Last review date of this leaflet: July 2022.
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.